Canthevac focuses on developing innovative vaccines and cancer therapeutics. Our integrated approach combines immunotherapy, AI-driven protein design, bioinformatics, microfluidics, viral vectors, and lipid nanoparticles. This groundbreaking platform enables the creation of effective vaccines for infectious diseases and cancers. We target pancreatic, colorectal, and non-small cell lung cancers using live-attenuated viral vectors, lipid nanoparticles, and AI-based neoantigens.